

Technology Advisory Committee C Interests Register

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis [ID1501]

Publication Date: 16 December 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Richard Nicholas	Committee Member	Financial	Dr Nicholas has attended paid advisory boards with Roche and Novartis for treatment in an unrelated area (MS).	N/A	08.06.2021	N/A	It was agreed that this declaration would not prevent Dr Nicholas from participating in the discussion of the appraisal.
Professor Stephen O'Brien	Committee Chair	Professional	In his role as a consultant haematologist, Professor O'Brien looks after patients with myelofibrosis but has no financial interests to declare.	N/A	16.06.2021	N/A	It was agreed that this declaration would not prevent Professor O'Brien from participating in the discussion of the appraisal.
Professor Matthew Stevenson	Committee Member	Non-financial	Professor Stevenson is employed by SchARR, the ERG for this appraisal. He confirmed he was not involved in the production or peer review of the ERG report.	N/A	14.05.2021	N/A	It was agreed that this declaration would not prevent Professor Stevenson from participating in the discussion of the appraisal.

Professor Paul Tappenden	Committee Member	Non-financial	Professor Tappenden is employed by SchARR, the ERG for this appraisal. He confirmed he was not involved in the production or peer review of the ERG report.	N/A	14.05.2021	N/A	It was agreed that this declaration would not prevent Professor Tappenden from participating in the discussion of the appraisal.
Professor Claire Harrison	Clinical expert	Financial	Professor Harrison was chief investigator for the JAKARTA2 study and involved with JAKARTA1. She has also received payment for speaking and advisory boards. Her institute has received research grants from Celgene as well as other companies.	N/A	29.05.2020	N/A	It was agreed that these declarations would not prevent Professor Harrison from providing expert advice to the committee.
Professor Adam Mead	Clinical expert	Financial	Professor Mead has participated in advisory boards for Novartis, Celgene/Bristol-Myers Squibb (BMS) and Pfizer and received honoraria, research funding, travel, accommodations, and expenses from Novartis and Celgene/BMS. Professor Mead also noted that MPN Voice, the	N/A	26.05.2020	N/A	It was agreed that these declarations would not prevent Professor Mead from providing expert advice to the committee.

			organisation which nominated him, received a grant of £10,000 from Celgene in 2019 as support for National Patient Day, and an application to Celgene for financial support has been granted, but funds not yet received (£10,000 as support for patient events).				
--	--	--	---	--	--	--	--